Pancreatic Cancer Drug Daraxonrasib Nearly Doubles Survival in Late-Stage Trial

At the American Society of Clinical Oncology's annual meeting in Chicago on Sunday, something rare happened in the austere world of cancer research: the audience stood and applauded. The moment came as researchers presented data on daraxonrasib, an experimental oral drug developed by Revolution Medicines, which had achieved what oncologists have long struggled to accomplish—a meaningful extension of life for patients with pancreatic cancer, one of the most lethal malignancies known.

The numbers told the story. In a trial involving 500 patients, those who received daraxonrasib lived for a median of 13.2 months. Those given standard chemotherapy lived for 6.7 months. That gap—nearly doubling survival time—represented something the medical community had not seen before in a Phase 3 pancreatic cancer trial, regardless of which line of treatment patients were receiving. For a disease that kills most of those it touches, the difference between six months and thirteen months is not merely statistical. It is time: time with family, time to plan, time to live.

The trial focused specifically on cancers driven by RAS mutations, a genetic alteration present in more than nine in ten pancreatic cancer cases. This precision mattered. Rather than a drug that worked broadly and weakly, daraxonrasib targeted the specific molecular driver of the disease in the vast majority of patients who would need it. The drug was also gentler. Patients taking it reported fewer side effects than those undergoing chemotherapy, meaning that the extra months of life came without the severe toll that traditional treatment exacts.

Mark Goldsmith, the chief executive and chairman of Revolution Medicines, framed the finding in language that reflected both scientific confidence and clinical significance. He called the results a watershed moment—one that positioned daraxonrasib as a new standard of care for patients with metastatic pancreatic cancer that had already been treated once. More than that, he suggested, the drug represented the opening of an entirely new therapeutic frontier, one built on targeting the RAS mutations that had long resisted effective treatment.

Wall Street analysts took note. Cory Kasimov at Evercore called the oncology community's response a clear signal that daraxonrasib would become a historic launch in the field. He also suggested that market expectations for the drug, even after being revised upward, were likely still too conservative. The financial world was catching up to what the doctors in that Chicago auditorium already understood: this was a significant moment.

The path forward is moving quickly. Revolution Medicines plans to submit the trial data to the Food and Drug Administration through a fast-track approval process, a designation that can compress the typical review timeline to as little as two months. The FDA has already authorized an expanded access program, meaning that eligible patients who cannot wait for formal approval will have the opportunity to receive the drug now. For people living with pancreatic cancer—a diagnosis that has historically offered little hope and less time—that window matters enormously.